First report onoototoxicity of meglumine antimoniate

Valete-Rosalino, Cláudia Maria; Araujo-Melo, Maria Helena; Bezerra, Débora Cristina de Oliveira; Barcelos, Renata Oliveira de; Melo-Ferreira, Vanessa de; Torraca, Tânia Salgado de Sousa; Martins, Ana Cristina da Costa; Moreira, João Soares; Vargas, Mirian Catherine Melgares; Braga, Frederico Pereira Bom; Salgueiro, Mariza de Matos; Saheki, Maurício Naoto; Schubach, Armando Oliveira.
Rev. Inst. Med. Trop. Säo Paulo ; 56(5): 439-442, Sep-Oct/2014. graf
Artículo en Inglés | LILACS | ID: lil-722321

Similares

  1. First report on ototoxicity of meglumine antimoniate.
  2. [Cutaneous leishmaniasis and multidermatomic herpes zoster].
  3. A Randomized, Controlled, Noninferiority, Multicenter Trial of Systemic vs Intralesional Treatment With Meglumine Antimoniate for Cutaneous Leishmaniasis in Brazil.
  4. [Cardiotoxicity of n-methyl-glucamine antimoniate (Glucantime). A case report].
  5. Self-reporting of hearing loss and tinnitus in the diagnosis of ototoxicity by meglumine antimoniate in patients treated for American tegumentary Leishmaniasis.
  6. Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre.
  7. Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial.
  8. Comparison of Meglumine Antimoniate and Miltefosine in Cutaneous Leishmaniasis.
  9. Nephrotoxicity attributed to meglumine antimoniate (Glucantime) in the treatment of generalized cutaneous leishmaniasis.
  10. Should we continue to indicate meglumine antimoniate as first-line treatment for cutaneous leishmaniasis in Tunisia.